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Summary Data on myelodysplastic syndromes (MDS) are seldom collected by cancer registries and unbiased
findings from population-based studies remain rare. We report detailed information on MDS in a well-defined
French population in the period 1980-1990. The crude incidence rate was 3.2 per 100 000 per year and no
significant change in incidence was noted in the study period. The sex ratio was 1.9 and the male predominance
was present in all age groups. We observed a rise in incidence after 60 years of age but no significant change in
incidence of MDS as a whole was observed over the period studied. Refractory anaemia with excess of blasts
(RAEB) was the most frequent subtype. Overall 5 year transformation rate of MDS was 31% (±4%) but it
was 100% in RAEB in transformation. The observed 5 year survival rate was 23% +3% and the corresponding
corrected rate was 33%. The prognosis of RAEB in transformation was worse than the prognosis of other
subtypes (P<0.01). Discrepancies with epidemiological data from other European countries are discussed.
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The myelodysplastic syndromes (MDS) are a heterogeneous
group of acquired haematological disorders. They are all
characterised by quantitative and qualitative defects within
one to three cell lines arising from the malignant
transformation of a multipotent stem cell (Janssen et al.,
1989). Despite this, MDS were not considered as malig-
nancies in the ninth International Classification of Diseases
(ICD-9) (WHO, 1977). This situation explains why data on
MDS are rarely collected by cancer registries. So knowledge
on epidemiological characteristics of MDS is often based on
statistics from selected populations, mainly hospital-based
statistics (Reizenstein and Dabrowski, 1991). Unbiased
results from population-based registries remain rare (Cart-
wright et al., 1990; Aul et al., 1992; Williamson et al., 1994).
The Registry of Haematopoietic Malignancies of the Cote
d'Or (France) area provides detailed information on MDS
since 1980. The purpose of this study was to provide
information on incidence and prognosis of MDS in a well-
defined French population.
Materials and methods
The department of Cote d'Or is located in Burgundy, France.
The population was 493 931 inhabitants according to the
1990 census. In this population, 46% live in the urban centre
of Dijon, 19% live in small towns and 35% live in rural areas
(INSEE, 1991). It is a relatively stable population with little
migration and few foreigners (6%).
A population-based registry specialised in haematopoietic
malignancies (HM) was created in 1980 in this area. Since
then all HM, including MDS, diagnosed in this population,
have been registered. The data presented consist of all
patients in whom a MDS was diagnosed between January
1980 and December 1990. Information was collected from
public and private biology and pathology laboratories, public
and private hospital departments, general physicians and
death certificates. Registration took place under excellent
conditions: all bone marrow smears were examined in the
C6te d'Or's single laboratory of haematology; biological
information existed for all cases and there was an average of
three notifications per case, and the morbidity/mortality ratio
was 2.4 (Carli et al., 1986). The efficiency of the registry was
confirmed by an audit by the National Institute for Health
and Medical Research (INSERM) in 1989 and 1993.
FAB classification of MDS was used i.e. refractory
anaemia (RA), refractory anaemia with ring sideroblasts
(RARS), refractory anaemia with excess of blasts (RAEB),
refractory anaemia with excess of blasts in transformation
(RAEB-t) and chronic myelomonocytic leukaemia (CMML)
(Bennett et al., 1982). Myelodysplastic syndromes with
myelofibrosis (MD with MF) were classified separately
(Lambertenghi-Deliliers et al., 1991). MDS were considered
as primary in the absence of previous bone marrow disorder
or treated neoplasia. MDS were considered as secondary
when they were diagnosed after a previous treated neoplasia
or an haematological malignancy.
Detailed distribution of the. population by age and sex
provided by the National Institute for Statistics and
Economic Studies (INSEE) was used to calculate incidence
rates. For the purpose of regional comparison, rates were
standardised by the direct method using the World Standard
Population. For the comparison of rates in urban and rural
areas within C6te d'Or the so-called indirect standardisation
method was used. The standardised incidence ratio (SIR) was
calculated as the ratio of observed cases vs expected cases.
Transformation rates and survival rates were calculated using
the life-table method. Corrected survival rates were
calculated, these being defined as the ratio of the observed
survival rates and the expected survival rates derived from
the French population life-tables. Transformation and
survival curves were compared by means of the log-rank
test. The health status of all patients was updated in
December 1993.
Results
Incidence
A total of 167 MDS were diagnosed among Cote d'Or
residents between 1980 and 1990. They represented 9.5% of
the 1754 registered cases of HM. The crude incidence rate
was 3.2 per 100 000 per year (3.8 in men and 2.5 in women).
The corresponding age-standardised rate was 1.7 per 100 000
per year (2.3 in men and 1.2 in women) (sex ratio, 1.9). Age-
specific incidence rates are given in Figure 1. There was a
male predominance in all age groups. MDS were rare before
the age of 60 (12%). After 60 incidence rose rapidly with age,
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February 1996more steeply in men than women. The mean age was 73 f
men and 74 for women (NS). The risk of MDS was higher
urban than in rural areas. For men the SIR was respective
1.31 and 0.60 (P<0.01). The corresponding figures f
women were 1.18 and 0.71 (NS).
RAEB was the most frequent subtype of MDS (330°
before RARS and CMML (21% each), RAEBt (13%), R
(8%) and MD with MF (4%). Analysis by sex showed a ma
predominance in all subtypes except for RA and MD wi
MF (Table I). RA was diagnosed in relatively young
patients than other MDS cases (three cases were diagnos
before 40 years) (mean age 64 years). On the other han
CMML was diagnosed later in life (mean age 78 year
Mean age for other MDS cases were 69 years for MD wi
MF, 71.5 years for RAEBt, 72 years for RAEB and 76 yea
for RARS. Overall, 146 MDS were classified as prima
(87%) and 21 as secondary (12.5%).
There was no significant change in incidence over t
studied period. Age-standardised rates for 100 000 inhal
tants were 1.5 for the 1980-82 period, 1.4 for the 1983-
period, 2.0 for the 1986-88 period and 1.7 for the 1989-
period. Rates by 3 year period and by sex revealed a 1.5-ft
increase in incidence in men between the 1980-82 (1.8) a]
the 1986-88 (2.7) periods but a stable rate in the 1989-
period (2.6). In women incidence rates did not increase, th
were 1.2 for the 1980-82 period, 0.1 for the 1983-85 peric
1.6 for the 1986-88 period and 1.1 for the 1989-90 peric
Progression and survival
Overall 5 year transformation rate of MDS was 31% (±4(
but it was different according to the subtype. For RAEBt t
1 year transformation rate was 44% and the 5 year rate w
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Figure 1 Age-specific incidence rates of MDS subtype per
100000 inhabitants per year in Cote d'Or. -*-, men; -x-,
women.
Table I Distribution ofcases of MDS by subtype diagnosed in C6te
d'Or between January 1980 and December 1990
Number of cases
FAB subtype M F Total (%)
RA 5 8 13(8%)
RARS 22 13 35 (21%)
RAEB 32 23 55 (33%)
RAEB t 12 10 21 (13%)
CMML 27 8 35 (21%)
MD with MF 2 5 7 (4%)
Total 100 67 167
MDS, myelodysplastic syndromes; RA, refactory anaemia; RARS,
refractory anaemia with ring sideroblasts; RAEB, refractory anaemia
with excess ofblasts; RAEB t, refractory anaemia with excess ofblasts
in transformation; CMML, chronic myelomonocytic leukaemia; MD
with MF, myelodysplastic sydromes with myelofibrosis. M, male; F,
female.
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100%. In contrast no transformation occurred in MD with
MF during the study period. For other MDS subtypes the 5
year transformation rate was 39% (±8%) for RAEB, 30%
(±9%) for CMML, 7% (±5%) for RARS and 17%
(±11%) for RA. All the transformed MDS were myeloid
leukaemias. Among them 54% were M2 FAB subtype (20/
37), 16% were M4 (4/37), 13% were MI (5/37), 8% were M5
(3/37), 5% were MO (2/37) and 3% were M6 (1/37) but none
were M3 FAB subtype. The observed 5 year survival rate was
23%+3% and the corresponding corrected rate was 33%.
Corrected 5 year survival rate was 0 for RAEBt, 24% for
RAEB, 33% for CMML, 34% for MD with MF, 35% for
RARS and 50% for RA. The prognosis of RAEBt was worse
than the prognosis of other subtypes (P<0.01). Corrected
survival curves according to the subtype of MDS are given in
Figure 2.
Discussion
90 Very little data are available on the incidence of MDS. Most
)ld of it concerns the United Kingdom (UK) (Cartwright et al.,
nd 1990; Williamson et al., 1994; Phillips et al., 1994). Incidence
90 rates have also been published for the Dusseldorf area (Aul et
Ley al., 1992). The reported data describe, for the first time, the
Dd, epidemiological characteristics of MDS in a well-defined
)d. French population.
The incidence of MDS in France appears to be close to
the incidence in Dusseldorf (4.1 per 100 000) or in England
and Wales (3.6 per 100 000) (Aul et al., 1992; Cartwright et
%) al., 1990). In the UK there are important variations in
the incidence according to areas. Very high incidence rates have
vas been reported in east Dorset (12.6 per 100 000) and Somerset
(9.3 per 100 000) (Williamson et al., 1994; Phillips et al.,
1994). This discrepancy does not seem to be attributable to
0 incomplete registration. Many reasons could explain these
differences. First of all the proportion of elderly people, in
whom MDS are more frequent, was higher in east Dorset
(22.5% were over 65) and in Somerset (25% were over 60)
than in our population (13.5% were over 65). The second
explanation mentioned was the well-established health-
screening of the elderly in these two regions. As 42% of
K MDS have been diagnosed in the event of an incidental blood
test in our area, more systematic blood tests in the elderly
population could explain part of the observed differences.
Furthermore, certain peripheral blood findings are difficult to
diagnose even for a specialist. In such cases only a bone
marrow examination can detect a MDS. Williamson et al.
(1994) made strenuous efforts to document new cases by
85 adopting a low threshold for performing marrow examina-
tion in patients with suggestive peripheral blood findings. It is
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Figure 2 Corrected survival rates of each subtype of MDS. -*-,
refractory anaemia; -*-, refractory anaemia with ring side-
roblasts; -x-, refractory anaemia with excess of blasts; -A-,
refractory anaemia with excess of blasts in transformation; -A-,
chronic myelomonocyte leukaemia.
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very probable that in some areas a bone marrow examination
was not provided in all patients, especially when they are
asymptomatic or stable or very old. For these reasons we
think that real incidence of MDS is higher than that generally
reported.
The well-established health screening of the elderly in
Dorset could also partly explain the repartition of MDS
subtypes diagnosed in their population. They noted a higher
proportion of often asymptomatic and quite stable MDS as
RA and CMML. Consequently RAEB and RAEBt are less
numerous. The greatest discrepancy is the number of RA: we
found only 8% of RA compared with 21% and 43% in the
other studies (Cartwright et al.. 1990; Aul et al., 1992:
Williamson et al.. 1994). An explanation could be the
harshness of our criteria for including RA. In addition to a
regenerative anaemia with dyserythropoietic features in bone
marrow. we required at least one other biological symptom of
MDS such as bone marrow haematopoietic progenitors.
abnormal in vitro growth pattern or abnormal karyotype at
diagnosis or during the follow-up. In fact RA is the most
difficult MDS to diagnose even for a specialist because of the
paucity of objective characteristics and we think that it is
often overevaluated. Other subtypes are as frequent in
England and Wales as in France.
The male predominance as found in our study had already
been pointed out (Cartwright et al.. 1990: Aul et al.. 1992).
No previous report has examined urban and rural differences.
Cartwright reported geographical variations in the UK but
did not consider urban rural variations (Cartwright et al..
1990). The explanation for the higher incidence in urban
areas is unknown: it may be the result of some unidentified
occupational or environmental exposure or some artefact of
the way the data were collected. In our register. the
proportion of secondary MDS, due to previous chemother-
apy amounted to 12.5% of all MDS.
A discrepancy between England and Germany and France
concerns the trends. Important increases in incidence have
been reported in England: a 2-fold increase between 1984 and
1988 and in Germany a 3-fold increase in incidence between
the 1976-80 and the 1986-90 periods (Cartwright et al..
1990: Aul et al.. 1992). In France incidence rates increased
but not so rapidly at the beginning of the decade and have
remained stable since 1988- 1989 (Figure 1). In Dusseldorf.
they also noted that the rates are quite stable in the later
years studied (Aul et al.. 1992). The increase generally
observed coincided with the publication in 1982 of the FAB
classification, which was responsible for a better knowledge
and an easier diagnosis of MDS (Bennett et al.. 1982).
No results have been published so far concerning
transformation rate in population-based statistics. Our data
allow consideration of three groups: RAEBt with a high risk
of transformation, which is nearly 50% 1 year after the
diagnosis and 100% at 5 years. MD with MF and RA with
the lower risk with a 5 year cumulative transformation rate
being less than 10%. and RAEB. CMML and RARS with an
intermediate 5 year risk ranging between 18% and 32%.
Similar results have been reported in hospital-based statistics
(Kerkhofs et al.. 1987).
Survival analysis confirms the worse prognosis of RAEBt.
RARS. MD with MF and CMML are equivalent in terms of
survival. CMML survival rate is close to some reports with a
median survival time of 50 months and different from other
studies in which it is worse (Fenaux et al., 1987: Mufti et al.,
1985: Tricot et al., 1984). This discrepancy could be owing to
selection bias in a haematological centre. as opposed to
population-based registries which include all diagnosed cases.
In RARS the 5 year transformation rate was quite low
whereas the survival rate was bad. The evolution of each
MDS subtype was different and the follow-up and the
therapeutic attitude have to be adjusted. Epidemiological
studies are necessary not only to establish epidermiological
features useful for public health attitudes but also to define
prognosis factors and generate suitable therapeutic schemes.
This is particularly true in western countries where the elderly
population is becoming more and more important.
Acknowledgements
We thank Professor Jean Faivre for his helpful criticism and Mrs J
Milan for her help in statistical work. The Registre des
Hemopathies Malignes de C6te dOr benefits from a research
grant from Comite Departmental of the Ligue Nationale Contre le
Cancer.
References
AUL C. GATTERMANN N AND SCHNEIDER W. (1992). Age-related
incidence and other epidemiological aspects of myelodysplastic
syndromes. Br. J. Haematol.. 82, 358-367.
BENNETT JM.. CATOVSKY D. DANIEL MT. FLANDRIN G. GALTON
DAG. GRANILCK HR AND SULTAN C. (1982). Proposals for the
classification ofthe myelodysplastic syndromes. Br. J. Haematol..
51, 189-199.
CARLI PM. MILAN C. LANGE A. DEVILLIERS E. GUY H AND
FAIVRE J. (1986). Haematopoietic malignancies in C6te d'Or
(France): a population based study. Br. J. Cancer. 53, 811 -815.
CARTWRIGHT R-A. ALEXANDER FE. MCKINNEY PA AND RICK-
ETTS TJ. (1990). Myelodysplastic states. In Leukemia and
Lvmphoma. An Atlas ofDistribution within Areas ofEngland and
Wales (1984-1988). pp. 32-40. Leukemia Research Fund:
London.
FENAUX P. JOUET JP. ZANDECKI M. LAZI JL. SIMON M. POLLET JP
AN-D BAUTERS F. (1987). Chronic and subacute myelomonocytic
leukemia in the adult: a report of60 cases with special reference to
prognostic factors. Br. J. Haematol.. 65, 101 - 106.
INSTITUT NATIONAL DE LA STATISTIQUE ET DES ETUDES
ECON-OMIQUES (INSEE). (1991). Resencement General de la
Population de 1990. INSEE: PARIS.
JANSSEN JWG. BUSCHLE M. LAYTON M. DREXLER HG. LYONS J.
VAN DEN- BERGHE H. HEIMPEL H. KUBANEK B. KLEIHAUER E.
MUFTI GJ AND BARTRAM CR. (1989). Clonal analysis of
myelodysplastic syndromes: evidence of multipotent stem cell
origin. Blood. 73, 248-254.
KERKHOFS H. HERMANS J. HAAK HL AND LEEKSMA CHW. (1987).
Utility of the FAB classification for myelodysplastic syndromes:
investigation ofprognostic factors in 237 cases. Br. J. Haematol..
65, 73-81.
LA-MBERTE.NGHI-DELILIERS G. ORAZI A. LUKSCH R. ANNAAROLO
C AND SOLIGO D. (1991). Myelodysplastic syndrome with
increased marrow fibrosis: a distinct clinico-pathological entity.
Br. J. Haematol.. 78, 161-166.
MUFTI GJ. STEVENS JR. OSCIER DG. HAMBLIN TJ AND MACHIN D.
(1985). Myelodysplastic syndromes: a scoring system with
prognostic significance. Br. J. Haematol.. 59, 1425-1433.
PHILLIPS MJ. CULL GM AND EWINGS M. (1994). Establishing the
incidence of myelodysplasia syndrome. Br. J. Haematol., 88,
896- 897.
REIZENSTEIN P AND DABROWSKI L. (1991). Increasing prevalence
ofthe myelodysplastic syndromes. An international Delphi study.
Anticancer Res.. 11, 1069- 1070.
TRICOT G. DE WOLF-PETERS C. HENDRICKX B AND VERWILGHEN
RL. (1984). Bone marrow histology in myelodysplastic syn-
dromes. I. Histological findings in myelodysplastic syndromes
and comparison with bone marrow smears. Br. J. Haematol.. 57,
423-430.
WILLIAMSON PJ. KRUGER AR. REYNOLDS PJ. HAMBLIN TJ AND
OSCIER DG. (1994). Establishing the incidence ofmyelodysplastic
syndrome. Br. J. Haematol.. 87, 743-745.
WORLD HEALTH ORGANIZATION (WHO). (1977). International
Classification ofDiseases. 9th revision. World Health Organiza-
tion: Geneva.